Paolo Tarantino and Sara Tolaney
Jun 1, 2025, 17:02
Paolo Tarantino: The practice-changing results from ASCENT-04 presented by Sara Tolaney
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared on X:
“Sara Tolaney presents the practice-changing results from ASCENT-04.
Among patients with PDL1+ mTNBC, first-line SG/pembrolizumab improved PFS vs chemo/pembrolizumab (11.2 vs 7.8 months, HR 0.65, p<0.001). Positive OS trend, despite built in crossover.
Huge news for a major unmet need in breast oncology!”
You can find more posts featuring Paolo Tarantino on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 12, 2025, 14:53
Jul 12, 2025, 14:38
Jul 12, 2025, 14:29
Jul 12, 2025, 14:27
Jul 12, 2025, 14:23
Jul 12, 2025, 14:16